Evidence map›Paper›PMID 36201707›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

Reply to C. Marchetti et al.

Bradley J Monk, Keiichi Fujiwara, David M O'Malley, Robert L Coleman, Iain A McNeish, Kevin K Lin, Stephanie Hume, Rebecca S Kristeleit

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Bradley J MonkBradley J. Monk, MD, GOG Foundation, HonorHealth Research Institute, University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ; Keiichi Fujiwara, MD, Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; David M. O'Malley, MD, Division of Gynecologic Oncology, The Ohio State University, James Cancer Center, Columbus, OH; Robert L. Coleman, MD, US Oncology Research, The Woodlands, TX; Iain A. McNeish, MD, Department of Surgery and Cancer, Imperial College London, London, United Kingdom; Kevin K. Lin, PhD, Molecular Diagnostics, Clovis Oncology Inc, Boulder, CO; Stephanie Hume, PhD, Clinical Development, Clovis Oncology Inc, Boulder, CO; and Rebecca S. Kristeleit, MD, Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.ORCID 0000-0001-6985-0159
Keiichi FujiwaraBradley J. Monk, MD, GOG Foundation, HonorHealth Research Institute, University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ; Keiichi Fujiwara, MD, Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; David M. O'Malley, MD, Division of Gynecologic Oncology, The Ohio State University, James Cancer Center, Columbus, OH; Robert L. Coleman, MD, US Oncology Research, The Woodlands, TX; Iain A. McNeish, MD, Department of Surgery and Cancer, Imperial College London, London, United Kingdom; Kevin K. Lin, PhD, Molecular Diagnostics, Clovis Oncology Inc, Boulder, CO; Stephanie Hume, PhD, Clinical Development, Clovis Oncology Inc, Boulder, CO; and Rebecca S. Kristeleit, MD, Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.ORCID 0000-0002-7388-0243
David M O'MalleyBradley J. Monk, MD, GOG Foundation, HonorHealth Research Institute, University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ; Keiichi Fujiwara, MD, Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; David M. O'Malley, MD, Division of Gynecologic Oncology, The Ohio State University, James Cancer Center, Columbus, OH; Robert L. Coleman, MD, US Oncology Research, The Woodlands, TX; Iain A. McNeish, MD, Department of Surgery and Cancer, Imperial College London, London, United Kingdom; Kevin K. Lin, PhD, Molecular Diagnostics, Clovis Oncology Inc, Boulder, CO; Stephanie Hume, PhD, Clinical Development, Clovis Oncology Inc, Boulder, CO; and Rebecca S. Kristeleit, MD, Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.ORCID 0000-0002-2828-0177
Robert L ColemanBradley J. Monk, MD, GOG Foundation, HonorHealth Research Institute, University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ; Keiichi Fujiwara, MD, Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; David M. O'Malley, MD, Division of Gynecologic Oncology, The Ohio State University, James Cancer Center, Columbus, OH; Robert L. Coleman, MD, US Oncology Research, The Woodlands, TX; Iain A. McNeish, MD, Department of Surgery and Cancer, Imperial College London, London, United Kingdom; Kevin K. Lin, PhD, Molecular Diagnostics, Clovis Oncology Inc, Boulder, CO; Stephanie Hume, PhD, Clinical Development, Clovis Oncology Inc, Boulder, CO; and Rebecca S. Kristeleit, MD, Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.ORCID 0000-0001-9343-8754
Iain A McNeishBradley J. Monk, MD, GOG Foundation, HonorHealth Research Institute, University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ; Keiichi Fujiwara, MD, Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; David M. O'Malley, MD, Division of Gynecologic Oncology, The Ohio State University, James Cancer Center, Columbus, OH; Robert L. Coleman, MD, US Oncology Research, The Woodlands, TX; Iain A. McNeish, MD, Department of Surgery and Cancer, Imperial College London, London, United Kingdom; Kevin K. Lin, PhD, Molecular Diagnostics, Clovis Oncology Inc, Boulder, CO; Stephanie Hume, PhD, Clinical Development, Clovis Oncology Inc, Boulder, CO; and Rebecca S. Kristeleit, MD, Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.ORCID 0000-0002-9387-7586
Kevin K LinBradley J. Monk, MD, GOG Foundation, HonorHealth Research Institute, University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ; Keiichi Fujiwara, MD, Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; David M. O'Malley, MD, Division of Gynecologic Oncology, The Ohio State University, James Cancer Center, Columbus, OH; Robert L. Coleman, MD, US Oncology Research, The Woodlands, TX; Iain A. McNeish, MD, Department of Surgery and Cancer, Imperial College London, London, United Kingdom; Kevin K. Lin, PhD, Molecular Diagnostics, Clovis Oncology Inc, Boulder, CO; Stephanie Hume, PhD, Clinical Development, Clovis Oncology Inc, Boulder, CO; and Rebecca S. Kristeleit, MD, Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.ORCID 0000-0003-4305-8352
Stephanie HumeBradley J. Monk, MD, GOG Foundation, HonorHealth Research Institute, University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ; Keiichi Fujiwara, MD, Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; David M. O'Malley, MD, Division of Gynecologic Oncology, The Ohio State University, James Cancer Center, Columbus, OH; Robert L. Coleman, MD, US Oncology Research, The Woodlands, TX; Iain A. McNeish, MD, Department of Surgery and Cancer, Imperial College London, London, United Kingdom; Kevin K. Lin, PhD, Molecular Diagnostics, Clovis Oncology Inc, Boulder, CO; Stephanie Hume, PhD, Clinical Development, Clovis Oncology Inc, Boulder, CO; and Rebecca S. Kristeleit, MD, Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.ORCID 0000-0002-8448-8917
Rebecca S KristeleitBradley J. Monk, MD, GOG Foundation, HonorHealth Research Institute, University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ; Keiichi Fujiwara, MD, Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; David M. O'Malley, MD, Division of Gynecologic Oncology, The Ohio State University, James Cancer Center, Columbus, OH; Robert L. Coleman, MD, US Oncology Research, The Woodlands, TX; Iain A. McNeish, MD, Department of Surgery and Cancer, Imperial College London, London, United Kingdom; Kevin K. Lin, PhD, Molecular Diagnostics, Clovis Oncology Inc, Boulder, CO; Stephanie Hume, PhD, Clinical Development, Clovis Oncology Inc, Boulder, CO; and Rebecca S. Kristeleit, MD, Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.ORCID 0000-0003-3825-1326

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID36201707

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.